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Abstract 
 
 
 
The purpose of this study was to examine the effect of a 2 minute bout of body weight 
support treadmill training (BWSTT) on ankle spasticity in persons with advanced multiple 
sclerosis (MS). Spasticity is a common symptom of MS, and is adversely associated with 
quality of life. Seven individuals with MS who had severely impaired ambulation participated 
in this investigation. Spasticity of both ankles was measured with two clinical scales; the 
Modified Ashworth Scale (MAS) and the Tardieu Scale (TS). The spasticity data were 
collected a total 3 times: 1) immediately following a 2 minute period of quiet sitting; 2) 
immediately following a 2 minute period of standing; and 3) immediately following a 2 
minute bout of BWSTT. The acute bout of BWSTT resulted in no reduction in the MAS and 
Tardieu Scale score. These results suggest that brief exposure to BWSTT has no immediate 
anti-spastic effect in persons with advanced MS.  
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1. Introduction 
Multiple Sclerosis 
Multiple Sclerosis (MS) is the most prevalent, non-traumatic chronic disabling 
neurologic disease among young and middle-aged adults (Freeman, 2001). There are 
approximately 400,000 people affected by MS in the United States, with an incidence 
of nearly 200 new cases confirmed each week (Rosati, 2001). MS typically involves 
inflammatory demyelination that manifests as lesions in the brain, brain stem, and 
spinal cord. These lesions result in motor command impairment of spinal pathways 
and networks (Hemmer et al., 2006;Bjartmar et al., 2001). Commonly reported 
symptoms in individuals include spasticity, sensory disturbances, limb weakness, 
fatigue, walking impairment, decreased balance, and cognitive deficit (Noseworthy, 
2000).  
Spasticity 
Spasticity is described as a motor disorder characterized by a velocity-
dependent increase in tonic stretch reflexes (“muscle tone”) and exaggerated tendon 
jerks resulting from hyper-excitability of the stretch reflex (Lance, 1980). Spasticity 
can range from a slight increase in muscle tone during movement to a considerable 
increase in muscle tone that makes even passive movement difficult (Lance, 1980).  
An estimated 84% of individuals with multiple sclerosis report spasticity (Rizzo et al., 
2004). In persons with MS, spasticity can occur throughout the body, but is most 
common in the lower limbs (Rizzo et al., 2004).  
The presence of spasticity in the lower limb is adversely associated with 
greater disability and quality of life (Rizzo et al., 2004). For instance, there is 
evidence that spasticity in the lower limbs affects mobility in persons with MS 
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(Sinkjaer et al., 1996). Additionally, there is evidence of an association between lower 
limb spasticity and postural control dysfunction (Sosnoff et al., 2010). In addition, 
Sosnoff and colleagues (2011) investigated the effects of spasticity on numerous 
aspects of mobility (walking speed, endurance, and self-reported walking impairment) 
and balance in 34 persons with MS with varying levels of spasticity. Participants were 
divided into groups based on the presence of ankle spasticity: spasticity group (n=15) 
and no-spasticity group (n=19). Overall, it was found that the spasticity group had 
more impairment of mobility and balance than the no-spasticity group (Sosnoff et al., 
2011).  
Spasticity Measurement 
The assessment of spasticity is important in persons with MS in order to 
facilitate clinical decision-making and to evaluate the effect of treatment. However, 
spasticity assessment methods remain a controversial topic (Biering – Sørensen et al., 
2006;Burridge et al., 2005). This controversy exists as a result of the complex nature 
of spasticity.  Spasticity exhibits a range of clinical manifestations and is further 
complicated by the accompanying disorders of the upper motor neuron syndrome.  
These varied characteristics suggest that different methods of measurement may be 
required to evaluate the different components of spasticity (Burridge et al., 2005).  
Consequently, several methods have been developed to assess spasticity.  They can be 
categorized as clinical, biomechanical, and neurophysiological assessments (Voerman 
et al., 2007).  
The main concept of the clinical spasticity scales is to quantify subjectively 
the amount of resistance to passive muscle stretch by a rater moving a limb through 
the range of motion. Several different clinical scales have been developed and used to 
assess spasticity, such as the Ashworth Scale (Ashworth, 1964), and the Tardieu Scale 
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(Gracies et al., 2000). Ashworth first introduced the Ashworth Scale, which contains 
four grades (in a range of 1 to 4), in a pharmacological study investigating the 
effectiveness of a muscle relaxant in persons with MS (Ashworth, 1964). Bohannon 
and Smith (1987) later modified the Ashworth Scale to the so-called “modified 
Ashworth Scale (MAS) by adding the grade “1+” between 1 and 2, in order to 
increase the sensitivity (Bohannon et al., 1987). In 1954, Tardieu proposed a concept 
defining spasticity as a velocity-dependent increase in stretch reflex and introduced a 
method to measure this conceptualization of spasticity (Tardieu et al., 1954). 
Following this introduction the Tardieu Scale (TS) was officially introduced by 
Gracies in 2000. The main difference between MAS and TS is that MAS does not 
take into account the velocity-dependent component of spasticity, whereas TS 
quantifies spasticity by measuring intensity of the muscle reaction at specified 
velocities (Pandyan et al., 1999;Gracies et al., 2001). All these clinical scales are 
subjective, as they depend on the perception of the examiner or patient. However, 
they can be performed in limited amounts of time and they do not require any 
specialized equipment. 
There are also biomechanical and neurophysiological ways to measure 
spasticity. These methods usually are used in laboratory setting. These approaches 
quantify spasticity quantitatively by assessing either the resistance to the imposed 
passive movement or the electrical activity of the involved muscles (Calota et al., 
2008) by using devices such as dynamometers, inertial sensors or electromyography 
(EMG). Previous investigations have utilized this methodology to assess the spasticity 
and confirmed their validity (Chung et al., 2008;De Vlugt et al., 2010). Although 
these biomechanical and neurophysiological methods are more reliable than clinical 
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scales, it is not practical to always use in clinical setting because of high cost and 
requirement of a significant amount of time and/or space.  
When assessing spasticity, it is important to note that body position can 
influence spasticity. This is based on the belief that spasticity is muscle length 
dependent (Burke et al., 1971;Ashby et al., 1971) since muscle length influences the 
amount of excitability of a-motor neuron pool or the neurophysiologic inhibitory 
effect (e.g., presynaptic inhibition)(Patikas et al., 2004).  In addition, Fleuren and 
colleagues (2006) investigated the influence of different body positions (sitting vs. 
supine) on spasticity by monitoring the stretch reflex activity of knee flexor and 
extensor muscles during the pendulum test and passive movement of the lower leg by 
using the surface electromyography (EMG) and the Ashworth Scale in post-stroke 
patients. It was found that different muscle length affected the amount of the stretch 
reflex activity with greater spasticity when the muscle is elongated. Thus different 
body positions influenced the outcome of neurophysiologic and clinical assessments 
of spasticity (Fleuren et al., 2006).  
Spasticity Management 
The management of spasticity is often multifaceted and can be broadly 
classified into two categories. One of these categories is the use of pharmacological 
agents for the management of spasticity (Rizzo et al., 2004 & Schapiro et al., 2005). 
For instance, baclofen is an agonist of γ-amniobutryic acid (GABA) receptors within 
the spinal cord and mediates a decrease in α-motor neuron pool excitability (Young, 
1994). Baclofen can be administered orally or intrathecally. Both delivery methods are 
commonly used in an attempt to reduce spasticity in persons with MS. Baclofen has 
been effective in reducing spasticity in individuals with MS and other neurological 
populations. Another example of a pharmacological agent for managing spasticity is 
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tizanidine. Tizanidine, a newer anti-spasticity medication, is a centrally acting α2 
adrenergic agonist, and may decrease spasticity through inhibition of release of 
excitatory amino acids (Young, 1994). Along with these benefits, anti-spastic 
medications are also associated with multiple drawbacks including the requirement of 
a prescription, high costs, and unwanted side effects including fatigue, muscle 
weakness, nausea, dizziness and functional limitations (Shakespeare et al., 2003). 
Additionally, the efficacy of these anti-spastic agents is questionable (Shakespeare et 
al., 2003). For instance, the results of one study reported that tizanidine administered 
either orally or through intramuscular injection had minimal acute or chronic effect on 
markers of spasticity (Thompson et al., 2005).  
Exercise is another therapeutic option for managing spasticity in persons with 
MS. Indeed, exercise has frequently been recommended as a behavioral approach for 
spasticity management (Thompson et al., 2005). There are increasing numbers of 
reports examining the effect of exercise for managing spasticity in persons with MS 
with mild to moderate impairment.  For instance, one study examined that the effect 
of a 30 minute bout of unloaded leg cycling exercise on the spasticity in 27 persons 
with MS who were not currently taking- anti spastic medications by utilizing soleus 
H-reflex and modified Ashworth scale. It was found that acute bout of unloaded leg 
cycling exercise was associated with a reduction in ankle spasticity in persons with 
MS. It was found that a single bout of unloaded leg cycling exercise was associated 
with a reduction in ankle spasticity in persons with MS. (Motl et al., 2006).  Another 
study examined the effect of a single 30 minute bout of unloaded leg cycling on the 
ankle spasticity in 6 individuals with MS who were currently taking oral anti-spastic 
medications. It was found that an acute bout of unloaded leg cycling exercise could 
offer an additive benefit to persons with MS who were taking oral anti-spastic 
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medications (Motl et al., 2007). A limitation of these studies is that the authors only 
examined spasticity in individuals with MS who were capable of performing leg 
cycling exercise without any supportive devices.  
Persons with MS who have severe mobility impairment are likely to be more 
limited in their ability to exercise. A potential exercise mode for persons with MS 
with severe mobility impairments is body weight supported treadmill training 
(BWSTT). BWSTT is a relatively new rehabilitative approach based on principles 
that promote the movement of the limbs and trunk to generate sensory information 
consistent with locomotion to improve the recovery of walking after serious 
neurologic injury or disease (Barbeau et al., 1987;Harkema, 2001;Finch et al., 1991). 
A pilot study examined the chronic effect of the BWSTT in a small group (n=4) of 
persons with advanced MS in EDSS range 7.0 and 8.0 (Geisser et al., 2007). Geisser 
reported that three out of four subjects showed reduction in spasticity as assessed by 
MAS after 20 weeks of BWSTT. These results suggest that BWSTT could be 
beneficial to reduce spasticity in individuals with MS who have severe mobility 
impairment. 
Although there is increasing evidence that acute or chronic exercise reduces 
spasticity in persons with MS with mild to severe impairment (Motl et al., 2006 & 
2007;Geisser et al., 2007) there is very little evidence regarding the application of 
acute BWSTT for reduction of spasticity in individuals with advanced MS. Further 
investigation is necessary to examine anti-spastic effect of BWSTT in different period 
in order to build appropriate therapeutic guideline for managing spasticity in persons 
with MS. The present study examined the effect of a 2 minute bout of body weight 
support treadmill training on ankle spasticity in persons with advanced MS. Based on 
extant data (Motl et al., 2006 & 2007;Giesser et al., 2007), it is predicted that acute 
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BWSTT would reduce spasticity in individuals with MS.  
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2. Method 
The procedures for this investigation were approved by the local Institutional 
Review Board. All participants provided written informed consent prior to undergoing 
experimental procedures.   
Participants 
The participant included 7 individuals with relapse-remitting (n = 4), primary 
progressive (n = 1), or secondary progressive (n = 2) MS who participate in ongoing 
body weight supported treadmill training intervention. Inclusion criteria for 
participants included a neurologist-confirmed diagnosis of MS, self-reported 
Expanded Disability Status Scale (EDSS) score between 6.0 and 8.0. Those with 
EDSS scores between 6.0 and 8.0 had moderate to severe disability (Kurtzke, 1983). 
However, they should be fully capable of completing a 2 minute bout of the body 
weight supported treadmill training. The mean age of the participants was 51 (S.D 
±13.4) years and 5 of the 7 participants were female. The average duration since the 
initial MS diagnosis was 14 (S.D ±8.1) years. Participant demographics are reported 
in Table 1.  
Table 1 Demographic of participant 
ID Age Gender Duration of MS EDSS Type of MS 
01 46 Male 8 7.5 Relapse-remitting 
02 25 Male 6 6.5 Primary progress 
05 65 Female 20 6.5 Relapse-remitting 
06 48 Female 6 7.0 Secondary progressive 
08 57 Female 22 6.5 Relapse-remitting 
19 54 Female 11 7.5 Relapse-remitting 
24 62 Female 25 6.0 Secondary progressive 
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Outcome measures 
The Modified Ashworth Scale (Bohannon et al., 1987) and the Tardieu Scale 
(Gracies et al., 2000) were used as measures of spasticity.  
Modified Ashworth Scale 
The MAS is a widely used qualitative scale for the assessment of spasticity. 
The MAS provides a measure of muscle hypertonia on a five-point scale; the scale 
starts from 0 to indicated normal tone and goes up to scale 4, an indicator of fixed 
muscle contracture (Bohannon et al., 1987). A full description of the MAS is 
presented in Table 2 
 
Table 2. Modified Ashworth Scale 
Scoring 
0 No increase in tone 
1 Slight increase in muscle tone, manifested by a catch and release or minimal 
resistance at the end of the range of motion when the affected part(s) is moved in 
flexion or extension 
1+ Slight increase in muscle tone, manifested by a catch, followed minimal 
resistance throughout the remainder (less than half) of the ROM 
2 More marked increase in muscle tone through most of the ROM, but affected 
part(s) easily moved  
3 Considerable increase in muscle tone, passive movement difficult 
4 Affected part(s) rigid in flexion or extension 
 
Tardieu Scale 
The TS quantifies muscle tone by measuring the intensity of the muscle 
reaction at specified velocities (Gracies et al., 2001).  A full description of the TS 
provided in table 3. The TS involves passively moving a limb through the range of 
motion at two velocities; as slow as possible (V1) and then as fast as possible (V3). 
Spasticity was quantified according to the criteria of muscle reaction for grades 0-4 
during the fast velocity (V3). The velocity of the limb segment falling under gravity 
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(V2) was not used in this study since it is not practical for some muscle groups 
(Gracies et al., 2001).  
 
Table 3. Tardieu Scale 
 
A. Velocities 
V1 As slow as possible 
V2 Speed of the limb segment falling under gravity 
V3 As fast as possible (faster that the rate of the natural drop of the limb segment 
under gravity) 
B. Scoring  
0 No resistance throughout the course of the passive movement 
1 Slight resistance throughout the course of passive movement, no clear catch at a    
precise angle 
2 Clear catch at a precise angle, interrupting the passive movement, followed by 
release 
3 Fatigable clonus with less than 10 seconds when maintaining the pressure and 
appearing at the precise angle 
4 Unfatigable clonus with more than 10 seconds when maintaining the pressure and 
appearing at a precise angle  
5 Joint is immovable 
Note: V1 is used to measure the passive range of motion (PROM).  Only V2 and V3 
are used to rate spasticity 
 
Body Weight Supported Treadmill Training  
During the body weight supported treadmill training (BWSTT) session, each 
participant was suspended by a harness and connected to a body weight support 
system above a treadmill as an example of the common configuration for a BWSTT 
session shown in Figure 1. While the participant was suspended in the harness, the 
body weight support system continuously regulated the amount of body weight 
assistance that was given to the participant so that the level of load on the lower limbs 
is controlled. This BWSTT session requires at least four trainers for a participant to 
safely complete the training session. While one person controls the computer, other 
trainers are positioned at each leg and at the trunk/pelvis assisted to facilitate 
movement in the participants’ ankles, legs, and hips. One session involves 
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approximately 60 minutes of weight bearing including a maximum of ten bouts of 
repetitive stepping where one single bout takes two minutes to perform.  
 
Figure 1. Body Weight Support Treadmill Training system. This figure is 
available online at http://www.ahs.illinois.edu/About/Gallery/Dedication.aspx#6 
 
Procedures  
A schematic outline of the experimental procedures is provided in Figure 2. 
Two trained clinicians assessed spasticity on participant’s both ankles by utilizing the 
MAS and the TS. Spasticity was measured in a total of three different conditions: 1) 
immediately following a 2 minute period of quiet sitting; 2) immediately following a 
2 minute period of standing; and 3) immediately following a 2 minute bout of 
BWSTT. The reason that spasticity was assessed in a total of three different body 
positions is to clarify if spasticity changes were associated with acute bout of BWSTT 
or just changing to different body positions.  
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Figure 2. A schematic outline of the experimental procedure  
Data Analysis 
Descriptive statistics of means and standard deviations were computed for all 
outcome measures. Differences between three conditions (sitting, standing, and 
BWSTT) were tested using a one-way analysis of variance (ANOVA). The 
significance level was set at p<0.05. No adjustments were performed for multiple 
comparisons due to the small sample size. Statistical analysis was performed by using 
SPSS version 19.0 (SPSS Inc., Chicago, IL, USA). 
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3. Results  
All seven participants completed the protocol. During the BWSTT, walking 
speed and % of body weight support were set for the walking bout based on 
participants’ mobility function. Walking speed, % of body weight support, and weight 
of the individuals during the BWSTT are reported in Table 4. The mean speed of 
walking was 1.4 (S.D ±0.5) MPH, and the mean % of body weight support was 41.4 
(S.D ±7.5).  
Table 4. Walking speed, % of body weight support, and weight of participant  
ID Speed (mph) % Body weight support Weight (kg) 
01 1.1 50% 86 
02 2.1 30% 54 
05 2.1 35% 42 
06 0.8 50% 77 
08 1.1 40% 61 
19 1.1 45% 91 
24 1.2 40% 50 
 
Spasticity was assessed on the soleus and gastrocnemius muscles of 7 
participants by two raters.  Spasticity of six participants was assessed on both ankles. 
Spasticity of one participant was assessed on only right ankle due to the history of the 
ankle fusion surgery on the left ankle. The scores of the two raters were averaged and 
the average of MAS and TS scores for three conditions is reported in table 5. There 
was no significant difference in the MAS and TS scores as a function of condition.  
 
Table 5. Average spasticity as a function of condition 
 MAS TS 
Condition M S.D. M S.D. 
Sitting 2.0 0.7 2.2 0.8 
Standing 1.9 0.8 2.2 0.9 
BWSTT 1.9 0.8 2.2 0.9 
Note: M=Mean, S.D.= Standard deviation  
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Modified Ashworth Scale 
The modified Ashworth Scale is provided in Figure 3. There was no change in 
6 of 7 participants. Only participant 2 showed a decrease in the MAS score on the 
ankle spasticity immediately following a 2 minute bout of BWSTT (Figure 3-A). 
Participant 6 and 24 demonstrated a decrease in MAS score following a 2 minute 
period of standing and a 2 minute bout of BWSTT (Figure 3-B). The ANOVA on 
MAS scores did not identify statistically significant differences between conditions in 
sitting, standing and BWSTT (F [2,36] = 0.079 p= 0.924).   
 
 
Figure 3. Modified Ashworth Scale score as a function of experimental condition 
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Tardieu Scale   
The Tardieu Scale data are illustrated in Figure 4.  Only participant 1 showed 
an improvement in the Tardieu scale on the ankle spasticity immediately following a 
2 minute bout of BWSTT (Figure 4-B). Participant 24 demonstrated a decrease in TS 
score following a 2 minute period of standing and a 2 minute bout of BWSTT (Figure 
4-A). Participant 6 demonstrated an increase in TS score following a 2 minute period 
of standing and BWSTT (Figure 4-B). The ANOVA on TS scores did not identify 
statistically significant differences between conditions in sitting, standing and 
BWSTT (F [2,36] = 0.031 P =0.969).  
 
 
Figure 4. Tardieu Scale score as a function of experimental condition 
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4. Discussion 
The purpose of this study was to investigate the effect of a 2-minute bout of 
body weight support treadmill training on ankle spasticity in persons with advanced 
multiple sclerosis (MS). Overall data showed that a 2 minute bout of BWSTT resulted 
in no reduction in spasticity that was indexed clinically with the MAS and TS scores. 
These results suggest that acute exposure to BWSTT has no anti-spastic effect on the 
ankle spasticity in persons with advanced MS.  
One potential explanation of the current finding is that the effect of BWSTT 
on clinical scales of spasticity in individuals with MS might depend on the acute 
versus chronic nature of the exercise stimulus. One investigation reports that 20 
weeks of the body weight supported treadmill training reduced spasticity on the ankle 
in small group of persons (n=4) with MS who had severe mobility impairments (e.g. 
inability to walk more than 25 feet) (Geisser et al., 2007). However, within present 
study, there was no a reduction in the MAS and TS score on the spasticity after a 2-
min bout of BWSTT in small group of persons (n=7) with advanced MS who had 
spasticity of the ankle joints. These results suggest that the effect of BWSTT on MAS 
and TS score might be chronic rather than acute in nature. This might indicate that 
BWSTT has beneficial implications in the long term instead of short term for 
managing spasticity in persons with advanced MS. One important suggestion for the 
future research involves examining the chronic anti-spastic effects of BWSTT with 
different dose of BWSTT.  
Another potential explanation for failure to demonstrate reduction in MAS and 
TS scores in persons with MS might be the duration of the exercise. Two studies 
reported that a 30 minute bout of unloaded leg cycling exercise reduced MAS scores 
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in persons with MS who had spasticity of the ankle joints (Motl et al., 2006 & 2007). 
In this study, exercise protocol was that participants underwent a 2 minute bout of 
BWSTT, and following exercise there was no change in MAS and TS score in 
spasticity on the ankle joints. Comparing to the duration of the cycling exercise which 
is a 30 minute bout in the previous research, current finding indicates that a 2 minute 
bout of BWSTT might be too short to reduce spasticity of ankle joint. One important 
suggestion for the future research involves examining the anti-spastic effects of 
BWSTT with different dose of BWSTT (e.g. 1 bout vs. 2 bouts, or 5 bouts vs. 10 
bouts) in persons with advanced MS. This would provide better therapeutic guidance 
to maximize anti-spastic effect of the BWSTT in persons with advanced MS for 
managing spasticity.  
The two different clinical spasticity measurements, MAS and TS, were used 
immediately following a 2 minute period of three different body conditions (sitting, 
standing, and BWSTT). However, these clinical measurement scales have been 
criticized for having poor reliability when assessing lower limb spasticity (Biering-
Sørensen et al., 2006;Van den Noort et al., 2010). A previous study examined that 
reliability of the TS on ankle spasticity in adult patients after stroke and they reported 
that reliability of the TS on ankle spasticity was insufficient for routine use in clinical 
settings and research (Ansari et al., 2013). A previous research by Bar-On (2013) 
involved quantifying spasticity on the gastrocnemius and hamstring muscles in 
children with cerebral palsy by integration of multidimensional signals. They reported 
that quantitative parameters, extracted from torque and EMG signal, and compared 
between velocity conditions were found to be sensitive and reliable to measure 
spasticity whereas the reliability of MAS and TS was questionable (Bar-on et al., 
2013). Another study involved using inertial sensors (MT9, Xsens Technologies, 
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Enschede, The Netherlands) to quantify spasticity in persons with cerebral palsy, and 
it was found that application of inertial sensors was sensitive when a precise 
measurement of spasticity was required (Van den Noort et al., 2008). This evidence 
suggested that measuring spasticity by utilizing different approaches such as 
biomechanical and neurophysiological methods should be considered to examine the 
acute effect of BWSTT on ankle spasticity in persons with advanced MS for the 
future study.  
It should be noted that this study is not without limitations. First, we were not 
able to investigate the anti-spastic effects of an acute bout of BWSTT for a duration 
greater than 2 minutes. A two minute period was chosen because a majority of 
persons with advanced MS have problems with muscle weakness and fatigue. A 
significant amount of physical effort is required to complete a bout of BWSTT from 
them. Thus it is important to decide an appropriate duration of a bout of BWSTT to 
prevent injuries or excessive fatigue for persons with advanced MS. In addition, 
training a participant for a bout of BWSTT requires a considerable amount of physical 
effort for trainers as well. Therefore, in order to prevent both fatigue and injuries for 
all involved, the duration of one bout of BWSTT was set as 2 minutes.  
Another limitation to this study is the difficulty of utilizing quantitative 
techniques. Measuring spasticity by employing different approaches such as 
biomechanical and neurophysiological methods was suggested to objectively quantify 
the reduction of ankle spasticity after a bout of BWSTT in persons with advanced MS 
(Bar-on et al., 2013;De Vlugt et al., 2010;Van den Noort et al., 2008). However, using 
biomechanical or neurophysiological methods require significance amount of time or 
space to complete and this procedure required spasticity to be measured as quickly as 
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possible following the three different conditions to avoid the influence of changing 
positions on spasticity.   
Furthermore, we did not investigate the effects of pharmacological agents on 
spasticity in the current study. Exercise is often recommended in combination with 
pharmacological agents for reducing spasticity (Schapiro et al., 2005) because 
medicines such as baclofen or tizanidine play an important role towards the 
management of spasticity in persons wit MS (Rizzo et al, 2004; Schapiro et al, 2005). 
Although an acute bout of BWSTT itself has no immediate anti-spastic effect in 
persons with advanced MS, there is no evidence identifying a synergy effect of 
BWSTT when combined with pharmacological agents. Future research is warranted 
to determine if an acute bout of BWSTT in combination with using pharmacological 
agents lead to reduction on spasticity in persons with advanced MS.  
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5. Conclusion 
 To our knowledge, this is one of the first investigations to identify an acute 
effect of exercise on lower limb spasticity in persons with advanced MS. This 
observation did not support the proposal that acute BWSTT would reduce spasticity 
in individuals with MS. The acute bout of BWSTT resulted in no reduction in the 
MAS and TS score. These results suggest that brief exposure to BWSTT has no 
immediate anti-spastic effect in persons with advanced MS.  
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